Liver-directed gene transfer in non-human primates

被引:104
作者
Sullivan, DE
Dash, S
Du, H
Hiramatsu, N
Aydin, F
Kolls, J
Blanchard, J
Baskin, G
Gerber, MA
机构
[1] TULANE UNIV,SCH MED,DEPT PATHOL & LAB MED,MOL CELLULAR BIOL GRAD PROGRAM,NEW ORLEANS,LA 70112
[2] LOUISIANA STATE UNIV,MED CTR,DEPT MED,NEW ORLEANS,LA 70112
[3] TULANE REG PRIMATE RES CTR,COVINGTON,LA
关键词
D O I
10.1089/hum.1997.8.10-1195
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
To develop a primate model for liver-directed gene therapy, we studied several gene transfer vehicles and routes in eight rhesus monkeys (Macaca mulatta). For this purpose, we used first-generation, replication-deficient adenoviral vectors carrying the Escherichia coli lacZ gene (Ad.CMVlacZ) or a lacZ-containing plasmid (pCMV beta) with lipofectamine for transfection. The reporter gene construct was infused into either the portal vasculature, common bile duct, or saphenous vein. Adenovirus-mediated gene transfer via the portal vein resulted in expression of lacZ in over 70% of hepatocytes by days 3-7, but was accompanied by acute hepatitis. Adenovirus-mediated gene transfer via the common bile duct resulted in lacZ expression in less than 10% of hepatocytes and was accompanied by portal inflammation. The animals mounted a significant immune response, as demonstrated by adenoviral antigen-induced T-cell proliferation and production of neutralizing anti-adenovirus antibodies and antibodies to E. coli beta-galactosidase (beta-Gal). Activation of the immune response was associated with rapid decrease of the reporter gene by days 13-21. Lipofectamine-mediated gene transfer was inefficient, and no lacZ expression in the liver was detected. To limit the host immune response, 4 animals were immunosuppressed by cyclophosphamide/prednisone and then infused with the Ad.CMVlacZ via the portal vein or the saphenous vein. The monkeys showed sustained expression of lacZ for up to 35 days with no evidence of inflammation. The primates transduced via the saphenous vein showed a level of beta-Gal expression in the liver similar to that of the portal vein-infused animals. In conclusion, adenovirus-mediated gene transfer to non-human primate livers via the portal vein or saphenous vein is efficient, but it results in transient expression and is accompanied by an immune response to both vector and transgene products and acute hepatitis, whereas lipofectamine-mediated transfer is inefficient. Manipulation of the host immune response may expand potential applications of adenoviral vectors for liver-directed gene transfer.
引用
收藏
页码:1195 / 1206
页数:12
相关论文
共 36 条
[1]   Liver-directed gene therapy: Molecular tools and current preclinical and clinical studies [J].
Alt, M ;
Caselmann, WH .
JOURNAL OF HEPATOLOGY, 1995, 23 (06) :746-758
[2]   INVIVO TRANSFECTION OF MURINE LUNGS WITH A FUNCTIONING PROKARYOTIC GENE USING A LIPOSOME VEHICLE [J].
BRIGHAM, KL ;
MEYRICK, B ;
CHRISTMAN, B ;
MAGNUSON, M ;
KING, G ;
BERRY, LC .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1989, 298 (04) :278-281
[3]   ADENOVIRUS-MEDIATED IN-VIVO GENE-TRANSFER [J].
BRODY, SL ;
CRYSTAL, RG .
GENE THERAPY FOR NEOPLASTIC DISEASES, 1994, 716 :90-103
[4]  
Curiel DT, 1996, AM J RESP CELL MOL, V14, P1
[5]   CELLULAR AND HUMORAL IMMUNE-RESPONSES TO ADENOVIRAL VECTORS CONTAINING FACTOR-IX GENE - TOLERIZATION OF FACTOR-IX AND VECTOR ANTIGENS ALLOWS FOR LONG-TERM EXPRESSION [J].
DAI, YF ;
SCHWARZ, EM ;
GU, DL ;
ZHANG, WW ;
SARVETNICK, N ;
VERMA, IM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1401-1405
[6]  
ENGLEHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196
[7]  
ENGLEHARDT JF, 1994, HUM GENE THER, V5, P1217
[8]   GENE-THERAPY FOR HEMOPHILIA-B - HOST IMMUNOSUPPRESSION PROLONGS THE THERAPEUTIC EFFECT OF ADENOVIRUS-MEDIATED FACTOR-IX EXPRESSION [J].
FANG, B ;
EISENSMITH, RC ;
WANG, H ;
KAY, MA ;
CROSS, RE ;
LANDEN, CN ;
GORDON, G ;
BELLINGER, DA ;
READ, MS ;
HU, PC ;
BRINKHOUS, KM ;
WOO, SLC .
HUMAN GENE THERAPY, 1995, 6 (08) :1039-1044
[9]   Improved cationic lipid formulations for in vivo gene therapy [J].
Felgner, PL ;
Tsai, YJ ;
Sukhu, L ;
Wheeler, CJ ;
Manthorpe, M ;
Marshall, J ;
Cheng, SH .
DNA VACCINES: A NEW ERA IN VACCINOLOGY, 1995, 772 :126-139
[10]   TRANSFER OF THE CFTR GENE TO THE LUNG OF NONHUMAN-PRIMATES WITH E1-DELETED, E2A-DEFECTIVE RECOMBINANT ADENOVIRUSES - A PRECLINICAL TOXICOLOGY STUDY [J].
GOLDMAN, MJ ;
LITZKY, LA ;
ENGELHARDT, JF ;
WILSON, JM .
HUMAN GENE THERAPY, 1995, 6 (07) :839-851